Chinese Vaccine Maker Inks Deal in Brazil for Final Testing
- Sinovac teams with drugmaker in test involving 9,000 people
- Chinese firms need to test shots where cases are active
The Sinovac Biotech facilities in Beijing.
Photographer: Nicolas Asfouri/AFP via Getty Images
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
China’s leading coronavirus vaccine developer signed an agreement with a drugmaker in Brazil to conduct further testing of its shot’s efficacy, as the global race intensifies to come up with the first viable candidate to prevent Covid-19.
Beijing-based Sinovac Biotech Ltd. is teaming up with Instituto Butantan to conduct the final phase of a three-part human testing of a vaccine it developed against the novel coronavirus, the company said in a statement. A Sinovac spokesman said it will need to obtain regulatory approval in Brazil before conducting the trial.